BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Aesica Joins Forces With Britest


2/14/2013 6:21:59 AM

Newcastle, 14 February, 2013 - Aesica, the global contract manufacturing organisation (CMO), announces that it will be joining Britest in a collaboration where members share knowledge and risk in defining innovative solutions to key manufacturing challenges.

Britest has already engaged with 22 leading global chemical and pharmaceutical organisations together with a number of academic organisations. The partnerships are designed to utilise and further develop Britest’s innovative tools and methodologies to support whole process understanding. In particular, Aesica will be utilising Britest’s expertise to identify new approaches and technologies that drive major improvements in API manufacturing processes.

The Aesica Innovation Board (AIB) aims to identify and commercialise new innovative technologies that help to bridge the growing R&D gap though industry and academic collaborations. Joining Britest will increase the AIB’s access to applicable, relevant technologies and strengthen the organisations relationships throughout the industry.

Dr Barrie Rhodes, Aesica Director of Technology Development said: “At Aesica we aspire to develop and implement new technologies and improve processes to support business growth. Following the successful demonstration of the Britest approach on a key Active Pharmaceutical Ingredient process at our Cramlington site, we are now looking forward to engaging fully in the Britest collaboration and implementing the Britest approach across a range of processes.”

Sue Fleet, Britest CEO said: “I am delighted to welcome Aesica Pharmaceuticals as our latest company member. With a clear focus on innovation and collaboration, we look forward to supporting Barrie and his colleagues at Aesica in driving innovative thinking and deriving full value from their membership of Britest.”

About Aesica:

Aesica supplies contract development and contract manufacturing services for Formulated Products and Active Pharmaceutical Ingredients to a host of the world’s leading pharmaceutical companies and emerging biotechnology organisations.

The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.

• Aesica is one of the UK’s fastest growing companies and over the last five years has more than trebled its turnover.

• The company currently employs approximately 1,300 people.

• In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy. It also has sales representation in San Diego and Shanghai.

• The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.

For media enquiries, please contact Alex Heeley or Tristan Jervis at De Facto Communications on: +44 (0) 20 7203 6740 or e-mail; t.jervis@defacto.com

About Britest:

Britest tools and methodologies are generally used in the design of new plant and processes, for trouble shooting, technology transfers, continuous/step-change process improvement, process scale-up and to better understand processes for risk assessment/business improvement. They employ a multi-disciplinary approach to managing knowledge and gaining whole process understanding across multi-functional teams.

Using a multi-disciplinary approach, Britest helps its members explore knowledge and understanding of their existing processes and implement process improvements through effective deployment of its proven tools and methodologies.

Britest’s members include some of the world’s leading companies with diverse interests across the pharmaceutical, fine chemical, mining, fuel additives and consumer products sectors. This industrial focus is uniquely complemented by some of the most respected international academics with a wealth of knowledge and expertise in the field of manufacturing and process design. The benefit of this international collaboration enables Britest to establish a coherent view on the key global manufacturing issues facing its members.

Since inception in 1998, Britest has delivered over €500 million of value to its member companies through reduced capital and operating cost, improved production efficiencies and product quality, reduced waste and improved energy efficiency.

Britest is a not-for-profit company owned and directed by its member organisations. It holds a bank of intellectual property for the innovative tools and methodologies that have been developed successfully through unique collaborative programmes amongst members. These collaborations help provide an opportunity for companies (large and small) to share knowledge and reduce risks in defining new process solutions.

Britest’s current members are: Abbvie, Albany Molecular Research (AMR)I, Anglo Platinum, AstraZeneca, Chemie Uetikon, Foster Wheeler, Fujifilm Imaging Colorants, GlaxoSmithKline, Hovione, Infineum, Isochem, Johnson Matthey, Takeda-Millennium, Pfizer, Procter & Gamble, Robinson Brothers, Shasun Pharma Solutions, The University of Newcastle, The University of Nottingham, Purdue University, USA and the Institution of Chemical and Engineering Sciences (ICES), Singapore.

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 203 6740. E-mail: t.jervis@defacto.com


Read at BioSpace.com


Aesica
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->